Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
Durvalumab plus carboplatin and etoposide was tolerable and expected to be effective in elderly patients with ES-SCLC.
Authors
- Hidenobu Ishii
- Takashi Inagaki (ORCID: https://orcid.org/0000-0002-6025-2571)
- Naoki Shingu
- Hiroshi Ishii (ORCID: https://orcid.org/0000-0002-1568-3161)
- Hiroshige Yoshioka (ORCID: https://orcid.org/0000-0001-7724-0481)
- Shinsuke Tsumura (ORCID: https://orcid.org/0000-0001-9813-9761)
- Yuko Tsuchiya‐Kawano
- Yuta Yamanaka (ORCID: https://orcid.org/0009-0009-7872-4395)
- Takayuki Shimose
- Yoshifusa Koreeda
- Yasushi Hisamatsu
- Chiho Nakashima (ORCID: https://orcid.org/0000-0001-7918-7282)
- Hiroyuki Inoue (ORCID: https://orcid.org/0000-0002-8071-8797)
- Isamu Okamoto (ORCID: https://orcid.org/0000-0002-7587-6096)
- Kazunori Tobino (ORCID: https://orcid.org/0000-0002-3456-6833)
- Masaki Okamoto (ORCID: https://orcid.org/0000-0002-9298-3504)
- Yukihiro Toi (ORCID: https://orcid.org/0000-0001-5983-3531)
- Taishi Harada (ORCID: https://orcid.org/0000-0002-5145-9036)
- Katsuhiko Naoki (ORCID: https://orcid.org/0000-0002-9637-1388)
- Koichi Azuma
- Keiko Mizuno
Institutions
- Kurume University (JP)
- Kagoshima University (JP)
- Kansai Medical University (JP)
- Kyushu University (JP)
- Saga University (JP)
- Oita University (JP)
- National Kyushu Medical Center (JP)
- Fukuoka University (JP)
- Kyushu Economic Research Center (JP)
- Fukuoka University Hospital (JP)
- Saiseikai Kumamoto Hospital (JP)
- Kyushu Hospital (JP)
- Oita Prefectural Hospital (JP)
- Kitakyushu Municipal Medical Center (JP)
- National Hospital Organization (JP)
- Aso Iizuka Hospital (JP)
- Tokushima Hospital (JP)
- Kumamoto Medical Center (JP)
- Sendai Kousei Hospital (JP)
- Kitasato University (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100836
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- MedImmune